SCHEMBL1242071

SCHEMBL1242071

Fc1ccc(NCC2CCCC2)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.50
CNR2 P34972 2/20 0.50
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
POLB P06746 1/20 0.47
HTT P42858 1/20 0.46
MAPK9 P45984 1/20 0.44
GAA P10253 1/20 0.44
KDM4C Q9H3R0 2/20 0.42
OPRL1 P41146 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ASPH Q12797 1/20 0.40
RIOX2 Q8IUF8 1/20 0.40
KDM8 Q8N371 1/20 0.40
ALDH1A1 P00352 2/20 0.40
ALDH3A1 P30838 1/20 0.40
SHMT2 P34897 1/20 0.40
HTR2C P28335 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL739595 0.86 NPC1 (0.43) CNR1CNR2NPC1RAB9APOLB
SCHEMBL1241609 0.83 AAK1 (0.46) KDM4CKDM4EASPHRIOX2KDM8
SCHEMBL20460623 0.82 NPC1 (0.42) NPC1RAB9AHTTGAAKDM4C
SCHEMBL20460622 0.82 KDM4C (0.42) CNR1CNR2KDM4CKDM4EASPH
SCHEMBL6229052 0.77 KMT2A (0.46) NPC1RAB9APOLBGAAKDM4C
SCHEMBL1240858 0.77 EPHX2 (0.46) KDM4CKDM4EASPHRIOX2KDM8
SCHEMBL1240818 0.77 ASPH (0.37) CNR1CNR2NPC1RAB9AKDM4C
SCHEMBL18208424 0.76 NPC1 (0.47) CNR1CNR2NPC1RAB9AOPRL1
SCHEMBL8170629 0.75 CNR1 (0.41) CNR1CNR2NPC1RAB9APOLB
SCHEMBL13438991 0.74 CNR2 (0.49) CNR1CNR2NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586614-B2 Urea glucokinase activators NOVO NORDISK A/S (DK) 2013-11-19 US disclosed
US-20110077234-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2011-03-31 US disclosed
US-7884210-B2 {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes NOVO NORDISK A/S (DK) 2011-02-08 US disclosed
US-20090105482-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
EP-1904467-A1 UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006814-A1 UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105482-A1 Urea Glucokinase Activators GCK, GCKR, HK2 CNR1 4160/4885CNR2 3508/4885NPC1 4026/4885
US-20110077234-A1 Urea Glucokinase Activators GCK, GCKR, HK2 CNR1 4160/4885CNR2 3508/4885NPC1 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.